Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients

We retrospectively collected clinical data on 31 relapsed or refractory acute myeloid leukemia (R/R AML) patients who were treated with outpatient glasdegib and low-dose Cytarabine (LDAraC) at our institution. The median age was 67 years (45–86). The median Eastern Cooperative Oncology Group perform...

Descripción completa

Detalles Bibliográficos
Autores principales: Zucenka, Andrius, Maneikis, Kazimieras, Pugaciute, Birute, Ringeleviciute, Ugne, Dapkeviciute, Austeja, Davainis, Linas, Daukelaite, Guoda, Burzdikaite, Paulina, Staras, Vytautas, Griskevicius, Laimonas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930524/
https://www.ncbi.nlm.nih.gov/pubmed/33661333
http://dx.doi.org/10.1007/s00277-021-04471-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930524/
https://www.ncbi.nlm.nih.gov/pubmed/33661333
http://dx.doi.org/10.1007/s00277-021-04471-6

Ejemplares similares